In this CMEO Snack entitled, Early Detection, Better Direction: Tau Biomarkers and Amyloid-Targeting Therapies in Alzheimer’s Disease, expert faculty will discuss strategies for identifying the neuropathological chances associated with AD, assessing the role of phosphorylated tau biomarkers, evaluating latest data from clinical trials on ATTs, and identifying appropriate patients to ensure timely and optimal management.
Henrik Zetterberg, MD, PhD, is Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London (UCL), UK, and a clinical chemist at Sahlgrenska University Hospital in Gothenburg, Sweden. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg, leads the UK DRI Fluid Biomarker Laboratory at UCL, and is a key member of the Hong Kong Center for Neurodegenerative Diseases and Visiting Professor in the University of Wisconsin (UW) Department of Medicine, School of Medicine and Public Health, Madison, Wisconsin. His main research focus and clinical interest are in fluid biomarkers for brain diseases, neurodegenerative diseases in particular. He has published more than 2,000 scientific articles and received many awards.
Chronic kidney disease (CKD) is a common comorbidity among patients with non-valvular atrial fibrillation (NVAF) and/or venous thromboembolism (VTE). Paradoxically, declining kidney function increases both thromboembolic and bleeding risks in patients with these conditions, requiring a fragile balance when implementing anticoagulation therapy to prevent ischemic stroke, deep vein thrombosis, and pulmonary embolism. Adding to the complexity of decision-making is a paucity of robust study results, as patients with CKD were often excluded from large anticoagulation clinical trials for patients with NVAF and VTE. Fortunately, newer studies and a wealth of real-world experience now provide practical guidance to optimize quality of care and outcomes. In particular, some of the direct oral anticoagulants (DOACs) have shown significant safety and efficacy versus warfarin in many patients with CKD and NVAF/VTE, but these therapies are still underused or underdosed because of clinician concern for increased bleeding.
In this CME Outfitters activity, experts in cardiology and nephrology discuss the challenges of striking the ideal risk-benefit ratio in anticoagulation for renally-impaired patients with NVAF or VTE. They explore the roles that shared decision making and recognition of each patient’s social determinants of health play in improving adherence to therapies. Importantly, the faculty demonstrates how cultural humility and awareness of implicit bias, particularly in communities of color, can improve equitable care and ensure best outcomes.
Sorry, no posts found.
In this CME Outfitters Snack, expert faculty will discuss biomarker research findings presented at the Alzheimer’s Association International Conference (AAIC), review the identification and measurement of AD pathophysiology, examine a framework for evidencing biomarker profiles of AD, provide updates on prognostic performance and interpretation of biomarkers, and conduct a case-based discussion of clinical impacts and applications.
Henrik Zetterberg, MD, PhD, is Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London (UCL), UK, and a clinical chemist at Sahlgrenska University Hospital in Gothenburg, Sweden. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg, leads the UK DRI Fluid Biomarker Laboratory at UCL, and is a key member of the Hong Kong Center for Neurodegenerative Diseases and Visiting Professor in the University of Wisconsin (UW) Department of Medicine, School of Medicine and Public Health, Madison, Wisconsin. His main research focus and clinical interest are in fluid biomarkers for brain diseases, neurodegenerative diseases in particular. He has published more than 2,000 scientific articles and received many awards.
Dr. Eric Tangalos is Professor of Medicine at the Mayo Clinic in Rochester, Minnesota. He served as Chair of Primary Care Internal Medicine from 1997 to 2006. Dr. Tangalos received his undergraduate training from the University of Michigan, is a graduate of the Loyola University Stritch School of Medicine in Chicago, and was a resident and fellow in Internal Medicine at Mayo.
He is a past president of AMDA, The Society for Post-Acute and Long-Term Care Medicine, and is a fellow and past governor of the American College of Physicians. He is a past director of the American Geriatrics Society and serves on their Foundation for Health in Aging. Dr. Tangalos served 8 years on the national board of the Alzheimer’s Association and was a member of their executive committee. He also served as Chair of the Omnicare P&T Committee for 20 years.
Dr. Tangalos was Medical Director at the Samaritan Bethany nursing home from 1981 until his retirement from Mayo in 2019. His certification as a medical director is current and will be approved again by the American Board of Post-Acute and Long-Term Care Medicine (ABPLM) in June 2022. He is currently recredentialed by Mayo for continuing service both to the Rochester campus and the Health Care System in Minnesota. Over the past 3 years he has worked face-to-face with patients in Austin and has provided in-basket coverage to Austin, Albert Lea, Faribault, and Owatonna.
Dr. Tangalos has been an investigator with the Mayo Clinic Alzheimer’s Disease Research Center since 1987 and is currently active with the Alzheimer’s Association as course director for a Project ECHO seminar series. Additionally, Dr. Tangalos continues to review NIH SBIR/STTR grant applications while working as a founding member of the American Telemedicine Association.
In this CME Outfitters Snack, expert faculty will review data presented at the Alzheimer’s Association International Conference (AAIC) and will focus on established, new, and emerging ATTs as well as a case-based discussion on clinical impacts and applications to provide point-of-care tactics that will have a positive impact on patient outcomes.
Nicolas Villain, MD, PhD, is a tenured Associate Professor of Neurology at Sorbonne University, Paris, France and a cognitive and behavioral neurologist at the Institute of Memory and Alzheimer’s Disease, Department of Neurology, Pitié-Salpêtrière Hospital, Paris. He trained as an MD and a clinical fellow in Paris in Prof. Bruno Dubois’ group and carried out his PhD with Dr. Gaël Chételat in Caen, France, where he worked on multimodal neuroimaging and disconnection mechanisms in Alzheimer’s disease. He currently leads projects on brain network vulnerability using multimodal neuroimaging and on fluid biomarkers of Alzheimer’s disease in Prof. Kaj Blennow’s new group at the Paris Brain Institute.
Dr. Eric Tangalos is Professor of Medicine at the Mayo Clinic in Rochester, Minnesota. He served as Chair of Primary Care Internal Medicine from 1997 to 2006. Dr. Tangalos received his undergraduate training from the University of Michigan, is a graduate of the Loyola University Stritch School of Medicine in Chicago, and was a resident and fellow in Internal Medicine at Mayo.
He is a past president of AMDA, The Society for Post-Acute and Long-Term Care Medicine, and is a fellow and past governor of the American College of Physicians. He is a past director of the American Geriatrics Society and serves on their Foundation for Health in Aging. Dr. Tangalos served 8 years on the national board of the Alzheimer’s Association and was a member of their executive committee. He also served as Chair of the Omnicare P&T Committee for 20 years.
Dr. Tangalos was Medical Director at the Samaritan Bethany nursing home from 1981 until his retirement from Mayo in 2019. His certification as a medical director is current and will be approved again by the American Board of Post-Acute and Long-Term Care Medicine (ABPLM) in June 2022. He is currently recredentialed by Mayo for continuing service both to the Rochester campus and the Health Care System in Minnesota. Over the past 3 years he has worked face-to-face with patients in Austin and has provided in-basket coverage to Austin, Albert Lea, Faribault, and Owatonna.
Dr. Tangalos has been an investigator with the Mayo Clinic Alzheimer’s Disease Research Center since 1987 and is currently active with the Alzheimer’s Association as course director for a Project ECHO seminar series. Additionally, Dr. Tangalos continues to review NIH SBIR/STTR grant applications while working as a founding member of the American Telemedicine Association.
In this CME Snack, expert faculty will discuss how to better identify the impact of symptoms on QoL and work, school, and/or psychosocial functioning for pediatric and adult patients with narcolepsy.
Dr. Anne Marie Morse is the Director of Child Neurology and Pediatric Sleep Medicine at Geisinger, Janet Weis Children’s Hospital. She has significant clinical and research experience and interest in children, adolescents, and adults with sleep wake disorders, particularly central disorders of hypersomnolence. In addition, her research interests extend more broadly to include investigating the relationship between sleep and neurologic and neurodevelopmental disorders. Dr Morse’s commitment to sleep health extends into the community. She has developed a school-based sleep education and surveillance program called Wake Up and Learn. This program was developed to provide education about sleep health and perform school-based sleep screening to improve recognition of pediatric sleep disorders in middle and high school students. It has now expanded to include learners in college, medical school, and medical residency programs with a clinical and health plan delivery, called Sleep to Be Well. Dr. Morse envisions a world where sleep can be acknowledged as the vital sign of health, wellness, and performance that it is designed to be.
Dr. Bogan is the President of Bogan Sleep Consultants, LLC. He is also Associate Clinical Professor at the University of South Carolina School of Medicine and Associate Clinical Professor at the Medical University of South Carolina in Charleston, SC.
Dr. Bogan received his bachelor’s degree in chemistry from Wofford College and his MD degree from the Medical University of South Carolina in Charleston. He served his internship and residency, as well as Chief Medical Resident, at the University of Alabama Hospital and Clinics in Birmingham. Thereafter, he completed a fellowship and assistant professorship in the Pulmonary Division of the Department of Medicine at the University of Alabama School of Medicine. He has been certified by the American boards of Sleep Medicine, Internal Medicine, and Pulmonary Diseases.
Dr. Bogan has served as principal investigator on numerous clinical trials in the past and continues to do so now. He has a variety of publications and research interests that focus on topics such as narcolepsy, insomnia, sleep apnea, shift work sleep disorder, restless legs syndrome/periodic limb movement disorder, chronic fatigue/fibromyalgia, and circadian rhythm abnormality.